Significats de hematologic toxicities en anglès

Patients with acceptable hematologic toxicities were eligible to receive additional cycles until progression.

The most frequently observed adverse events included fatigue (86%) and hematologic toxicities.

Typically, the hematologic toxicities resolved shortly after SAHA was stopped.

Hepatic and hematologic toxicities were evaluated by biochemical analysis.

Adverse events following (90)Y-IT consolidation were primarily transient hematologic toxicities.

Although hematologic toxicities were common, only one patient was removed from study due to prolonged myelosuppression.

Treatment breaks arising during concurrent ChT+RT were used to manage severe symptomatic or hematologic toxicities.

Moreover, because of pelvic irradiation, toxicities, especially hematologic toxicities, are increased and require a drug dose reduction.

All patients developed CTEP grade 1 or 2 metabolic or hematologic toxicities.

The most common acute toxicities were grades 3-4 hematologic toxicities and stomatitis.

Severe hematologic toxicities were rare.

Common hematologic toxicities of grade 3 or 4 included anemia and neutropenia in both groups.

There were significantly greater hematologic toxicities, documented infections, and transfusions of RBCs and platelets in the higher-dose plus rhGM-CSF group.

Patients of 3.4-4.7% experienced severe hematologic toxicities during the treatment with concomitant CTX and NTZ.

Overall, grade 3 or worse adverse events were rare, with hematologic toxicities occurring in 5.8%.

Grade 3 and 4 hematologic toxicities occurred in 28 (32.1%) patients in the ACNU-CDDP group, but there were no treatment-related deaths.